Compare Oxford Lane Capital Corp (OXLC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Repligen Corporation Common Stock — how do they compare? Oxford Lane Capital Corp trades at $8.22 (market cap $817.57M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 13.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.78% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 51 Days and Repligen Corporation Common Stock for 0 Days on average.
| OXLC | RGEN | |
|---|---|---|
Market Cap | $817.57M | $11.14B |
Volume | 2,300,089 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $16.02 | $194.57 |
52-Week Low | $8.15 | $102.87 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $1.21B | $11.02B |
Dividend Yield | 28.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.
The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
